Citations

Clear

3314 citation(s) found for "Yu, Alexander".

1386: MECHANICAL VENTILATION TRAINING STANDARDIZATION: INTERNATIONAL MODIFIED DELPHI SURVEY
Manjappachar, Nirmala, Kılıçkaya, Oğuz , Wang, Baiyong , Chu, Kim Duc, Gajic, Ognjen, Oeckler, Richard A. , Dong, Yue , Niven, Alexander S. , Lal, Amos

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001104208.99705.59 Get It

389: COMPARATIVE EVALUATION OF MACHINE TRANSLATION/AI TOOLS IN INTERNATIONAL CRITICAL CARE EDUCATION
Chen, Christine , Zambrano, Claudia Castillo , Bencheqroun, Hassan, Hoffman, Adria, Boulekbache, Oualid, Dong, Yue , Hoffman, Adria, Barwise, Amelia , Niven, Alexander S.

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001100220.80613.de Get It

1100: ASSESSING MECHANICAL VENTILATION TRAINING FOR ICU CLINICIANS: A GLOBAL NEEDS ASSESSMENT SURVEY
Wang, Baiyong , Zambrano, Claudia Castillo , Manjappachar, Nirmala, Kılıçkaya, Oğuz , Lin, Leqing , Chen, Lin , Gajic, Ognjen, Dong, Yue, Kantas, Dimitrios, Niven, Alexander S.

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001103064.49437.a0 Get It

Bots in white coats: are large language models the future of patient education? A multicenter cross-sectional analysis
Aghamaliyev, Ughur , Karimbayli, Javad , Zamparas, Athanasios, Bösch, Florian, Thomas, Michael , Kahlert, Christoph , Nieß, Hanno , Guba, Markus , Ilmer, Matthias, Schmidt, Thomas, Krautz, Christian , Schölch, Sebastian , Angele, Martin Kurt , Werner, Jens Martin , Ilmer, Matthias , Renz, Bernhard Willibald

Mayo Clinic

International Journal of Surgery | January 29, 2025 | Volume: 111 | Issue: 3 | Pages: 2376-2384

10.1097/js9.0000000000002250 | PMID 39878073 Get It

Objectives: Every year, around 300 million surgeries are conducted worldwide, with an estimated 4.2 million deaths occurring within 30 days after surgery. Adequate patient education is crucial, but often falls short due to the stress patients experience before surgery. Large language models (LLMs) can significantly enhance this process by delivering thorough information and addressing patient concerns that might otherwise go unnoticed. Material and methods: This cross-sectional study evaluated Chat Generative Pretrained Transformer-4o’s audio-based responses to frequently asked questions (FAQs) regarding six general surgical procedures. Three experienced surgeons and two senior residents formulated seven general and three procedure-specific FAQs for both preoperative and postoperative situations, covering six surgical scenarios (major: pancreatic head resection, rectal resection, total gastrectomy; minor: cholecystectomy, Lichtenstein procedure, hemithyroidectomy). In total, 120 audio responses were generated, transcribed, and assessed by 11 surgeons from 6 different German university hospitals. Results: ChatGPT-4o demonstrated strong performance, achieving an average score of 4.12/5 for accuracy, 4.46/5 for relevance, and 0.22/5 for potential harm across 120 questions. Postoperative responses surpassed preoperative ones in both accuracy and relevance, while also exhibiting lower potential for harm. Additionally, responses related to minor surgeries were minimal, but significantly more accurate compared to those for major surgeries. Conclusions: This study underscores GPT-4o’s potential to enhance patient education both before and after surgery by delivering accurate and relevant responses to FAQs about various surgical procedures. Responses regarding the postoperative course proved to be more accurate and less harmful than those addressing preoperative ones. Although a few responses carried moderate risks, the overall performance was robust, indicating GPT-4o’s value in patient education. The study suggests the development of hospital-specific applications or the integration of GPT-4o into interactive robotic systems to provide patients with reliable, immediate answers, thereby improving patient satisfaction and informed decision-making.
The year in cardiovascular medicine 2024: the top 10 papers in cardio-oncology
Herrmann, Joerg , López‐Fernández, Teresa , López-Fernández, Teresa , Lyon, Alexander R.

Mayo Clinic

European Heart Journal | January 28, 2025 | Volume: 46 | Issue: 13 | Pages: 1186-1188

10.1093/eurheartj/ehaf019 | PMID 39873207 Get It

Clinical outcome after complete response with immunotherapy in hepatocellular carcinoma.
Chen, Pin‐Jung , Kournoutas, Ioannis , Sanford, Alison, Adetyan, Hasmik , Rezaee‐Zavareh, Mohammad Saeid , Ayoub, Walid S. , Kaymen, Emily, Hendifar, Andrew , Yang, Ju Dong , Sanford, Alison, Kim, Naomy , Kuo, Alexander , Kaymen, Emily A. , Tran, Nguyen H. , Yang, Ju Dong

Mayo Clinic

Journal of Clinical Oncology | January 27, 2025 | Volume: 43 | Issue: 4_suppl | Pages: 573-573

10.1200/jco.2025.43.4_suppl.573 Get It

573 Background: Immunotherapy has shown great efficacy in hepatocellular carcinoma (HCC). No clear consensus exists on when to stop the immune checkpoint inhibitor (ICI) after complete response (CR), and clinical course after stopping ICI remains unknown. Methods: We identified 138 HCC patients who received ICI at Cedars-Sinai Medical Center and Mayo Clinic Rochester from 2016-2023. Modified Response Evaluation Criteria In Solid Tumors (mRECIST) was used to assess treatment response. We further described the clinical course of patients who achieved CR after ICI discontinuation, including cancer recurrence, subsequent treatment, liver transplantation (LT) listing and outcomes. Results: The median age at ICI initiation was 68 years; 79% were male; 55.9% were white; 51.5% were BCLC stage C. 9.4% CRs, 25.4% partial responses, 39.9% stable diseases, and 25.4% progressive disease. Hepatitis C etiology was associated with higher likelihood of CR (P=0.005). Among 13 patients who achieved CR, 10 stopped ICI (60% for LT evaluation, 40% for toxicity). After stopping ICI, 40% had recurrence (Table). 3 patients underwent local therapy for recurrent HCC within Milan criteria and 1 patient restarted ICI for recurrence beyond Milan criteria. Among CR patients, 9 patients underwent LT evaluation after stopping ICI and 7 patients were waitlisted. After listing, 3 dropouts were observed, due to recurrent HCC beyond Milan criteria, sepsis leading to death, and personal preference. 4 patients underwent LT. 2 patients underwent local therapy before LT for recurrent HCC (Table). All transplanted patients had the last dose of ICI more than 1 year before LT (12, 21, 24, and 29 months). On explanted livers, 2 patients had no residual viable tumor and 2 patients had residual HCC within Milan criteria. 1 patient developed acute cellular rejection and was treated with immunosuppressants and maintained stable graft function. None had graft loss or evidence of HCC recurrence in the follow-up period at 8, 20, 28, and 51 months. Conclusions: Immunotherapy demonstrated excellent effects on a subset of HCC patients, including 9.4% who achieved CR. After stopping ICI, 40% had cancer recurrence but 3 out of 4 were within Milan criteria. 4 underwent successful LTs (2.9%) with excellent post LT outcome. Larger prospective data is needed to establish a protocol for ICI use, especially to determine the optimal timing for ICI discontinuation after CR. BCLC at ICI initiation ICI cycles before stopping, ICI Recurrence after last ICI (days) Within Milan at recurrence Treatment(s) received after recurrence and outcomes OS (days) Patient 1 B 7, Nivolumab 730 No Nivolumab. Died from GI bleeding 1065 Patient 2 B 64, Atezo/Bev 149 Yes TACE with CR, followed by LT without recurrence. 1203 Patient 3 A 8, Nivolumab 1393 Yes Y90 with CR. No recurrence. 1984 Patient 4 C NA, Pembrolizumab 407 Yes TACE and MWA with CR, followed by LT without recurrence. 1722
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS
Allegretti, Jessica R. , Feuerstadt, Paul , Knapple, W , Orenstein, Robert , Pinton, Philippe , Sheh, Alexander , Khanna, Sahil , Feuerstadt, Paul

Mayo Clinic

Inflammatory Bowel Diseases | January 25, 2025 | Volume: 31 | Issue: 8 | Pages: 2112-2122

10.1093/ibd/izae291 | PMID 39862395 Get It

Abstract Background Fecal microbiota, live-jslm (RBL; REBYOTA®), is the first single-dose, broad consortia, microbiota-based live biotherapeutic approved by the US Food and Drug Administration to prevent recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care antimicrobials. Inflammatory bowel disease (IBD) is a common risk factor for rCDI, yet patients with IBD are often excluded from prospective trials. This subgroup analysis of PUNCH CD3-OLS (NCT03931941) evaluated the safety and efficacy of RBL in participants with rCDI and IBD. Methods Participants with IBD (ulcerative colitis [UC], Crohn’s disease [CD], or unspecified) who had rCDI were included. Treatment-emergent adverse event (TEAE) data were collected for up to 6 months following RBL administration. Efficacy outcomes included treatment success at 8 weeks and sustained clinical response at 6 months. Results Overall, 793 participants were enrolled, and 697 received RBL; 74 had IBD (UC: n = 45; CD: n = 25; unspecified IBD: n = 4). TEAEs within 8 weeks of administration were reported by 45.9% and 47.5% of participants with and without IBD, respectively; most were mild or moderate gastrointestinal symptoms. Serious TEAEs within 8 weeks of administration were reported by 1.4% and 4.2% of participants with and without IBD, respectively. The treatment success rate at 8 weeks was 78.9%, and the sustained clinical response rate at 6 months was 91.1% in participants with IBD, similar to rates in participants without IBD (73.2% and 91.0%, respectively). Conclusions The results of this subgroup analysis of PUNCH CD3-OLS suggest RBL is safe and efficacious in patients with IBD.
Circulating and Magnetic Resonance Imaging Biomarkers of Intestinal Fibrosis in Small Bowel Crohn’s Disease
Dillman, Jonathan R. , Tkach, Jean A. , Bruining, David H. , Lu, Aiming , Kugathasan, Subra , Knight‐Scott, Jack, Adler, Jeremy, Minar, Phillip , Bonkowski, Erin , Jurrell, Holden, Swanson, Scott D. , Fei, Lin , Qian, Lucia, Towbin, Alexander J. , Kocaoğlu, Murat , Anton, Christopher G. , Imbus, Rebecca, Denson, Lee A. , Kugathasan, Subra , Minar, Phillip , Dillman, Jonathan R , Fletcher, Joel G. , Alazraki, Adina , Stidham, Ryan W , Adler, Jeremy, Trapnell, Bruce C. , Lopez‐Nunez, Oscar , Collins, Margaret H. , Dudley, Jonathan A.

Mayo Clinic

Inflammatory Bowel Diseases | January 24, 2025 | Volume: 31 | Issue: 5 | Pages: 1380-1391

10.1093/ibd/izae319 | PMID 39853252 Get It

Abstract Background We previously identified circulating and MRI biomarkers associated with the surgical management of Crohn’s disease (CD). Here we tested associations between these biomarkers and ileal resection inflammation and collagen content. Methods Fifty CD patients undergoing ileal resection were prospectively enrolled at 4 centers. Circulating CD64, extracellular matrix protein 1 (ECM1), GM-CSF autoantibodies (GM-CSF Ab), and fecal calprotectin were measured by ELISA. Ileal 3-dimensional magnetization transfer ratio (3D MTR), modified Look-Locker inversion recovery (MOLLI) T1 relaxation, diffusion-weighted intravoxel incoherent motion (IVIM), and the simplified magnetic resonance index of activity (sMaRIA) were measured by MRI. Ileal resection specimen acute inflammation was graded, and collagen content was measured quantitatively using second harmonic imaging microscopy. Associations between biomarkers and ileal collagen content were tested. Results Median (interquartile range [IQR]) age was 19.5 (16-33) years. We observed an inverse relationship between ileal acute inflammation and collagen content (r = −0.39 [95% confidence interval {CI}: −0.61, −0.10], P = .008). Most patients (33 [66%]) received biologics, with no variation in collagen content with treatment exposures. In the univariate analysis, CD64, GM-CSF Ab, fecal calprotectin, and sMaRIA were positively associated with acute inflammation and negatively associated with collagen content (P < .1). The multivariable model for ileal collagen content (R2 = 0.31 [95% CI: 0.11, 0.52]) included log CD64 (β = −.27; P = .19), log ECM1 (β = .47; P = .06), log GM-CSF Ab (β = −.15; P = .01), IVIM f (β = .29, P = .10), and IVIM D* (β = 1.69, P = .13). Conclusions Clinically available and exploratory circulating and MRI biomarkers are associated with the degree of inflammation versus fibrosis in CD ileal resections. With further validation, these biomarkers may be used to guide medical and surgical decision-making for refractory CD.
Optimizing Electroconvulsive Therapy With E-Field Modeling
Ren, Caili , Kung, Simon , Forester, Brent P. , Hermida, Adriana P., Petrides, Georgios, Seiner, Stephen J., Pagali, Sandeep R. , Yoon, Isabel A , Lapid, Maria I. , Croarkin, Paul E. , Opitz, Alexander , Mueller, Martina , Yoon, Isabel A.

Mayo Clinic

The Journal of ECT | January 24, 2025 | Volume: 41 | Issue: 4 | Pages: 281-285

10.1097/yct.0000000000001111 | PMID 39853304 Get It

Abstract Electroconvulsive therapy (ECT) is an effective treatment for severe depression, especially in treatment-resistant cases. However, its potential cognitive side effects necessitate careful dosing to balance therapeutic benefits and cognitive stability. Recent advances in electric field (E-field) modeling offer promising avenues to optimize ECT dosing. This review synthesizes current knowledge on E-field modeling in ECT and explores its clinical applications. It examines the variability in E-field strengths and distributions induced by ECT and their impact on clinical outcomes. Additionally, the relationship between E-field strengths, neuroplasticity, and therapeutic efficacy is discussed. Translational studies of E-field-informed ECT are highlighted, emphasizing individualized optimal amplitude dosing and potential clinical applications. This review provides useful insights into how E-field modeling can improve the effectiveness of ECT while minimizing adverse effects, helping guide future research and clinical practice.